Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer

Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study

The aim of this study was to assess the impact of adjuvant radioactive iodine therapy on the quality of life(QOL) in differentiated thyroid cancer patients and to identify independent factors affecting changes in the QOL.

Inclusion Criteria:

• Pathologically confirmed new diagnosis of differentiated thyroid cancer, recently treated by total thyroidectomy
• Must sign a consent form before treatment
• One year or more of follow-up after radioiodine ablation

Exclusion Criteria:

• Patients with follicular, Hürthle cell, poorly differentiated, medullary, or anaplastic thyroid carcinoma
• Pregnant or lactating women
• Patients that received adjuvant radioiodine treatment in the past
• Patients with other cancer